

Figure S2. Validation of the ABCC11-expressing adenoviruses. **(a)** Expression of matured-ABCC11 wild-type (WT) protein on the membrane vesicles. ABCC11 WT-expressing or mock membrane vesicles were subjected to immunoblotting analysis with the anti-ABCC11 antibody (09YT). G: glycosylated, Non-G: non-glycosylated form of the ABCC11 protein; **(b)** Estrone sulfate (E₁S) transport activities of ABCC11 in the presence or absence of ATP. E₁S transport into membrane vesicles was measured for 10 min. ATP-dependent incorporation of E₁S was detected in the ABCC11 WT-expressing vesicles, but not in control vesicles. The values are expressed as the mean ± S.D., $n = 3$. Statistical analyses for significant differences were performed according to Student's *t*-test (**, $p < 0.01$; N.S., not significantly different between groups).




Figure S3. Generation of ABCC11 R180 variant from the adenovirus vector. Thirty-six hours after the infection, ABCC11 R180 variant-expressing Hepa1.6 cells were treated with or without 2 μM MG132 for further 12 hours, then subjected to immunoblotting analysis with the anti-ABCC11 antibody (09YT). P: whole cell lysate of ABCC11 WT-expressing Hepa1.6 cells with both MG132 and PNGase F treatment as a positive control for band position of non-glycosylated ABCC11. α-Tubulin: a loading control. The result showed that ABCC11 R180 protein was not matured as glycoprotein but degraded by MG132-sensitive pathway, which is consistent with the previous report showing that ABCC11 R180 variant is recognized as endoplasmic reticulum-associated protein degradation (ERAD) substrate (Toyoda et al., *FASEB J.* 2009, 23, 2001–2013.).